Nine Chapters Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Nine Chapters Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-578	Closed	-$1.84M	–	632
2015 Q3	$1.84M	Sell	578 -300	-34%	-$1.16M	0.16%	179
2015 Q2	$3.51M	Buy	878 +363	+70%	+$1.4M	0.29%	74
2015 Q1	$2.06M	Buy	+515	New	+$2.36M	0.17%	160
2014 Q1	–	Sell	-313	Closed	-$1.09M	–	985
2013 Q4	$1.09M	Buy	313 +257	+459%	+$1M	0.11%	274
2013 Q3	$229K	Buy	+56	New	+$241K	0.03%	605

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nine Chapters Capital Management's ACOR Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of Acorda Therapeutics (ACOR) in Q4 2015, closing a stake of 578 shares — an estimated $1.84M sold.

Nine Chapters Capital Management first reported a position in ACOR in Q3 2013 and held it in 5 quarters. The position peaked at $3.51M in Q2 2015. 186 funds tracked by Wall St. Rank hold ACOR as of Q4 2015.

Nine Chapters Capital Management reported no remaining Acorda Therapeutics position as of Q4 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 578 Acorda Therapeutics shares in Q4 2015, an estimated $1.84M.
Nine Chapters Capital Management first reported a position in Acorda Therapeutics in Q3 2013 and held it in 5 quarters.
Nine Chapters Capital Management's Acorda Therapeutics position peaked at $3.51M in Q2 2015.
186 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.